SAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today issued the below letter to Company shareholders from CEO and President Punit Dhillon. For supplemental proxy materials and additional information regarding the Fiscal Year 2015 Annual Meeting of Shareholders, please visit OncoSec's website: http://oncosec.com/oncosec-issues-annual-letter-to-shareholders.
Dear Valued Shareholder,
As we work to develop new cancer treatments for patients, I would like to thank you for your ongoing support of OncoSec's programs and strategies. With your support, we continue to champion our company's purpose: to deliver safer and more effective cancer immunotherapies that can make a difference in the lives of patients. Looking ahead, I would like to provide an overview of our progress since the last Annual Shareholder Meeting.
OncoSec's clinical development strategy is focused on demonstrating that ImmunoPulse™ IL-12 is a rational choice for combination therapy with anti-PD-1 agents. We believe ImmunoPulse™ IL-12 has the ability to convert a significant proportion of non-responder patients into those who will respond to anti-PD1 agents, and have aligned our clinical pipeline to validate this hypothesis.
As we advance our clinical pipeline, we are also working to develop advanced devices capable of accessing difficult-to-reach tumors, investigating new therapeutic candidates, and exploring unique combination approaches. We have also finalized plans to move into a new facility by year's end. Our expanded headquarters will consolidate clinical, discovery research, and administrative operations into one well-equipped facility. This move enhances our development capabilities and provides OncoSec with a base of operations that matches the magnitude of our ambitions.
To maintain consistent communication with our shareholders, we are establishing a new cadence for external communications, which started recently with quarterly conference calls and the timing of our Annual Shareholder Meeting. Our Annual Shareholder Meeting will now closely follow the filing of our Annual Report on Form 10-K. These activities are designed to establish a more regular communications schedule and further enhance shareholder engagement.
We encourage all eligible shareholders to vote in accordance with the information outlined in our definitive proxy statement. Your vote is especially important to us this year, as we look to initiate an exciting new program: our 2015 Employee Stock Purchase Plan. This allows all OncoSec employees to share in our vision by purchasing stock directly from the Company. We believe this program will support our progress by ensuring that each member of our team has a personal stake in OncoSec's success.
We look forward to sharing updates on our upcoming milestones at our Annual Shareholder Meeting and throughout the year. Thank you again for your ongoing support and confidence in OncoSec as we continue to advance our immuno-oncology pipeline.
Sincerely, Punit Dhillon CEO and President
About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse™, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as interleukin-12 (IL-12). In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse™ IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse™ IL-12 is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of OncoSec. Forward-looking statements are subject to risks and uncertainties, which may cause actual results to differ materially from current expectations. These risks and uncertainties include, among others, the following: our ability to raise additional funding necessary to fund continued operations on reasonable terms or at all; our ability to protect our intellectual property; uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; delays in the commencement or completion of clinical testing for product candidates; unexpected new data, safety and technical issues; our ability to develop and commercialize the assets we have acquired or develop and any new assets and product candidates; and competitive, market and regulatory conditions. Other risks and uncertainties are described in OncoSec's annual report on Form 10-K filed on October 14, 2015, and subsequent filings with the U.S. Securities and Exchange Commission made by OncoSec. Except as required by law, OncoSec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Investor Relations: Jordyn Kopin OncoSec Medical Incorporated 855-662-6732 firstname.lastname@example.org
Media Relations: Mary Marolla OncoSec Medical Incorporated 855-662-6732 email@example.com
SOURCE OncoSec Medical Incorporated